logo-loader
viewScancell Holdings PLC

Scancell unveils funding plans for exciting pipeline of next-generation cancer drugs

In a separate announcement, the company said it was acquiring new technology from Nottingham University that will complement its current pipeline

female researcher at microscope
The company has outlined what it plans in the next phase of development

Immunotherapy specialist Scancell Holdings Plc (LONSCLP) has raised £6.9mln net of expenses in a discounted placing and share subscription, with the cash to be used develop its three main drug candidates.

The stock was sold to investors at 14p, 31% below last's night's close.

WATCH: Scancell to raise up to £8mln to develop its three main drug candidates

The combined proceeds will be used to fund a phase II trial of the company’s lead drug, SCIB-1, in combination with a checkpoint inhibitor to treat late-stage melanoma.

Cancer Research UK 

Cash will also be deployed to support the Cancer Research UK development of SCIB2 for non-small-cell lung cancer.

And it will be used to begin a first-in-human study of Modi-1 in patients with triple-negative breast cancer, ovarian cancer and sarcoma planned to start in the first-half of next year.

In a separate announcement, Scancell said it had acquired a number of unique monoclonal antibodies to tumour-associated glycans that have the potential, when coupled with a method of activating the immune system, to provide a new class of cancer immunotherapy.

“We believe this platform complements our existing ImmunoBody and Moditope platforms, significantly broadening the strength and potential of Scancell's immunotherapy pipeline," said chief executive Cliff Holloway.

 -- Updates with placing completion details, share price --

Quick facts: Scancell Holdings PLC

Price: 4.9 GBX

LSE:SCLP
Market: LSE
Market Cap: £22.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Scancell to raise up to £8mln to develop its three main drug candidates

Cliff Holloway, chief executive at Scancell Holdings Plc (LONSCLP), tells Proactive Investors they're raising up to £8mln through a placing and open offer – cash that will be used develop their three main drug candidates. A placing and subscription at 12 pence a share will account for...

on 18/4/18

2 min read